Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating
Danaher's Q3 Earnings Boosted By Bioprocessing Order Growth, Analyst Maintain Stock Rating
On Tuesday, Danaher Corp (NYSE:DHR) reported third-quarter sales of $5.79 billion, up 3% year-over-year, beating the consensus of $5.59 billion.
週二，丹納赫公司（紐交所：DHR）報告第三季度銷售額爲57.9億美元，同比增長3%，超過了55.9億美元的共識。
Guidance: Danaher reaffirms that in fiscal year 2024, non-GAAP core revenue will be down in the low single digits year over year.
指導：丹納赫重申，到2024財年，非GAAP核心營業收入將同比下降個位數。
The company forecasts that 2024 bioprocessing core revenue will decline in the low single digits, and Cepheid 2024 respiratory revenues will be around $1.7 billion compared to prior guidance of $1.6 billion.
公司預測2024年生物加工核心營業收入將以個位數下降，而Cepheid 2024年呼吸道收入預計將達到約17億美元，相比之前的預測16億美元。
William Blair reports that Danaher's third-quarter earnings aligned with expectations, particularly regarding the ongoing recovery in bioprocessing, though capital expenditures remain weak.
William Blair報告稱，丹納赫第三季度的收益符合預期，尤其是生物加工行業的持續復甦，儘管資本支出仍然疲弱。
The analyst highlights that the recovery theme is progressing as anticipated, with results reflecting similar trends seen in industry conference updates earlier in the quarter.
分析師強調，復甦主題正如預期地發展，其結果反映了在季度初期行業會議更新中看到的類似趨勢。
Third-quarter book-to-bill improved to approximately 1.0x, up from 0.80x a year ago, and a high-single-digit increase in sequential orders further supported the bioprocessing rebound.
第三季度的訂單執行比提高至約1.0倍，高於一年前的0.80倍，而順序訂單的高單位數增長進一步支持了生物加工業的反彈。
In the equipment segment, life sciences instruments saw a mid-single-digit decline, in line with forecasts and intra-quarter observations.
在設備領域，生命科學儀器出現了中位數下降，符合預測和季中觀察的預期。
Meanwhile, diagnostics performed well, and Cepheid's respiratory revenue again exceeded expectations.
與此同時，診斷表現良好，Cepheid的呼吸道營收再次超出預期。
On guidance, management expects mid- to high-single-digit core growth in the fourth quarter in Biotechnology. The analyst expects the focus of the call will be on the fourth-quarter exit rate for bioprocessing, any initial insights into 2025, capital equipment weakness, and updated thoughts on China.
在指導方面，管理層預計生物技術行業第四季度核心增長率將在中高個位數。分析師預計，此次電話會議的重點將放在生物加工業第四季度退出率、對2025年的初步見解、資本設備疲軟以及對中國的最新看法上。
William Blair keeps the Outperform rating. Goldman Sachs maintains a Neutral rating, with a price target of $250.
William Blair繼續給予表現評級。高盛保持中立評級，目標股價爲250美元。
Price Action: DHR stock is down 4.01% at $261.18 at last check Tuesday.
股價走勢：丹納赫股票在上週二最後一次交易時下跌4.01%，報261.18美元。
Photo via Shutterstock
圖片來自shutterstock。
- With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says.
- 分析師表示，隨着FDA批准，iRhythm可能能夠消除監管擔憂、投資者懷疑。
譯文內容由第三人軟體翻譯。
